These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33051308)

  • 1.
    Muralidharan K; Yekula A; Small JL; Rosh ZS; Kang KM; Wang L; Lau S; Zhang H; Lee H; Bettegowda C; Chicoine MR; Kalkanis SN; Shankar GM; Nahed BV; Curry WT; Jones PS; Cahill DP; Balaj L; Carter BS
    Clin Cancer Res; 2021 Jan; 27(1):169-178. PubMed ID: 33051308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
    Fujioka Y; Hata N; Akagi Y; Kuga D; Hatae R; Sangatsuda Y; Michiwaki Y; Amemiya T; Takigawa K; Funakoshi Y; Sako A; Iwaki T; Iihara K; Mizoguchi M
    J Neurooncol; 2021 Mar; 152(1):47-54. PubMed ID: 33417137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma.
    Adachi JI; Shirahata M; Suzuki T; Mishima K; Uchida E; Sasaki A; Nishikawa R
    Brain Tumor Pathol; 2021 Jul; 38(3):201-209. PubMed ID: 34128111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
    Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
    EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
    Diplas BH; Liu H; Yang R; Hansen LJ; Zachem AL; Zhao F; Bigner DD; McLendon RE; Jiao Y; He Y; Waitkus MS; Yan H
    Neuro Oncol; 2019 Mar; 21(4):440-450. PubMed ID: 30346624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human TERT promoter mutations as a prognostic biomarker in glioma.
    Powter B; Jeffreys SA; Sareen H; Cooper A; Brungs D; Po J; Roberts T; Koh ES; Scott KF; Sajinovic M; Vessey JY; de Souza P; Becker TM
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1007-1017. PubMed ID: 33547950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
    Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
    Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
    Hewer E; Phour J; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):430-436. PubMed ID: 32068851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
    Groeneweg JW; Roze JF; Peters EDJ; Sereno F; Brink AGJ; Paijens ST; Nijman HW; van Meurs HS; van Lonkhuijzen LRCW; Piek JMJ; Lok CAR; Monroe GR; van Haaften GW; Zweemer RP
    Gynecol Oncol; 2021 Aug; 162(2):413-420. PubMed ID: 34083028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
    Li D; Bonner ER; Wierzbicki K; Panditharatna E; Huang T; Lulla R; Mueller S; Koschmann C; Nazarian J; Saratsis AM
    Sci Rep; 2021 Mar; 11(1):5098. PubMed ID: 33658570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Detecting Low Prevalence Somatic
    da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
    Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples.
    Corless BC; Chang GA; Cooper S; Syeda MM; Shao Y; Osman I; Karlin-Neumann G; Polsky D
    J Mol Diagn; 2019 Mar; 21(2):274-285. PubMed ID: 30827467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
    Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
    Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary
    Hosen MI; Forey N; Durand G; Voegele C; Bilici S; Avogbe PH; Delhomme TM; Foll M; Manel A; Vian E; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Boureille A; Pisarev E; Salas AROSE; Monteiro-Reis S; Henrique R; Byrnes G; Jeronimo C; Scelo G; McKay JD; Calvez-Kelm FL; Zvereva M
    Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
    Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
    Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
    Chen C; Han S; Meng L; Li Z; Zhang X; Wu A
    PLoS One; 2014; 9(6):e100297. PubMed ID: 24937153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
    Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
    Ishi Y; Okada H; Okamoto M; Motegi H; Tanaka S; Mitsuhashi T; Yamaguchi S
    Neuropathology; 2021 Jun; 41(3):236-242. PubMed ID: 33899270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatial Distribution Patterns of Clinically Relevant TERT Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential: Advantages of the Digital Droplet PCR Technique.
    Hysek M; Jatta K; Hellgren LS; Stenman A; Larsson C; Zedenius J; Juhlin CC
    J Mol Diagn; 2021 Feb; 23(2):212-222. PubMed ID: 33197629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
    Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
    Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.